Nuveen
CGEM icon

Nuveen’s Cullinan Oncology CGEM Stock Holding History

Nuveen’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.59M Sell
471,947
-333,753
-41% -$4.96M ﹤0.01% 1791
2026
Q1 		$11.4M Buy
805,700
+226,605
+39% +$2.91M ﹤0.01% 1467
2025
Q4 		$5.99M Buy
579,095
+363,500
+169% +$3.28M ﹤0.01% 1828
2025
Q3 		$1.28M Buy
215,595
+34,910
+19% +$256K ﹤0.01% 2502
2025
Q2 		$1.36M Sell
180,685
-7,345
-4% -$59K ﹤0.01% 2464
2025
Q1 		$1.42M Sell
188,030
-39,003
-17% -$374K ﹤0.01% 2478
2024
Q4 		$2.77M Sell
227,033
-6,533
-3% -$93.9K ﹤0.01% 2248
2024
Q3 		$3.91M Buy
233,566
+15,800
+7% +$280K ﹤0.01% 2102
2024
Q2 		$3.8M Buy
217,766
+124,544
+134% +$2.65M ﹤0.01% 2083
2024
Q1 		$1.59M Buy
93,222
+4,899
+6% +$75.7K ﹤0.01% 2500
2023
Q4 		$900K Buy
88,323
+9,707
+12% +$86K ﹤0.01% 2782
2023
Q3 		$711K Buy
78,616
+1,305
+2% +$13.6K ﹤0.01% 2717
2023
Q2 		$832K Buy
77,311
+5,103
+7% +$54.2K ﹤0.01% 2732
2023
Q1 		$739K Sell
72,208
-20,548
-22% -$227K ﹤0.01% 2708
2022
Q4 		$978K Sell
92,756
-14,604
-14% -$177K ﹤0.01% 2687
2022
Q3 		$1.38M Buy
107,360
+1,347
+1% +$18.1K ﹤0.01% 2588
2022
Q2 		$1.36M Sell
106,013
-1,455
-1% -$16.5K ﹤0.01% 2642
2022
Q1 		$1.38M Sell
107,468
-8,496
-7% -$115K ﹤0.01% 2682
2021
Q4 		$1.79M Sell
115,964
-77,228
-40% -$1.54M ﹤0.01% 2620
2021
Q3 		$4.36M Buy
193,192
+69,822
+57% +$1.87M ﹤0.01% 2285
2021
Q2 		$3.18M Buy
123,370
+73,634
+148% +$2.26M ﹤0.01% 2486
2021
Q1 		$2.07M Buy
+49,736
New +$2.02M ﹤0.01% 2599

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Nuveen's CGEM Position: Q2 2026 in Review

Nuveen reduced its Cullinan Oncology (CGEM) stake by 41% in Q2 2026, selling an estimated $4.96M and leaving 471,947 shares worth $8.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1791.

Nuveen first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. The position peaked at $11.4M in Q1 2026. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Nuveen held 471,947 shares of Cullinan Oncology worth $8.59M as of Q2 2026.
  • Nuveen sold 333,753 Cullinan Oncology shares in Q2 2026, an estimated $4.96M.
  • Cullinan Oncology made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1791 holding.
  • Nuveen first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • Nuveen's Cullinan Oncology position peaked at $11.4M in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.